Synthetic Biologics, Inc. SYN Cash Flow

Synthetic biologics, inc. (SYN)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11
Cash Flows From Operating Activities:
Net loss
-14,842	-15,380	-15,428	-13,967	-14,623	-13,421	-7,417	-14,659	-14,760	-15,492	-20,776	-18,334	-19,783	-27,803	-36,628	-35,646	-43,505	-44,785	-39,968	-37,371	-28,304	-19,784	-17,529	-15,987	-13,928	-12,318	0	0	0	-	-	-	-	-	-	-	-
Net loss
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-
Adjustments to reconcile net loss to net cash used in operating activities:
Net loss
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Net income from discontinued operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Stock-based compensation
359	340	612	996	1,462	2,074	2,211	2,636	2,950	3,409	4,009	4,056	4,092	4,009	4,045	3,744	3,423	3,198	2,691	2,655	2,924	2,459	2,294	2,022	1,574	1,669	1,750	1,807	1,800	1,851	1,793	1,454	713	973	0	0	0
Subsidiary stock issued to consultant
-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Subsidiary stock issues to vendor
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Warrant issued to vendor
-	-	-	-	-	9	9	9	9	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Stock issued for milestone payments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,350	-1,350	-1,350	-350	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Stock issued as compensation
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Stock issued for consulting fees
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	165	0	0	0
Change in fair value of warrant liabilities
-	-	-	-	-	-4,083	-12,645	-6,927	-8,303	-10,738	-9,888	-15,646	-17,000	-11,412	-3,776	-7,251	157	3,811	3,286	7,427	3,532	-620	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Depreciation
236	240	247	253	263	272	280	270	259	245	218	216	177	157	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Warrant expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,492	0	0	0
Change in fair value of warrant liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	242	0	0	0
Depreciation
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	0	-	45	47	54	63	62	82	84	144	0	0	0
Provision for uncollectible note and interest receivables
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	391	401	414	0	0	0
Changes in operating assets and liabilities:
Gain on the settlement of accounts payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	63	0	0	0
Accounts receivable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-14	55	190	412	480	0	0	0
Prepaid expenses and other current assets
224	788	634	764	254	-234	-705	-1,005	-2,760	-1,688	-1,827	-4,234	-3,750	-7,004	-7,240	-1,181	5,542	7,971	8,949	5,566	242	-43	-264	-428	-839	-855	1,609	1,837	2,202	2,544	0	0	0	-	-	-	-
Right of use asset
123	118	86	56	28	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other current assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Note receivable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Deposits and other assets
-	-	-	-	-	-	-	-	-	-	-	-	-	9	12	7	8	8	8	12	12	2	2	-9	-9	-33	-23	-5	-6	6	-6	-21	-2	-60	0	0	0
Gain on discontinued operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-
Assets of discontinued operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Accounts payable
481	1,282	1,573	306	-727	-987	-219	-505	-2,303	27	-3,144	-2,834	-801	-2,420	-1,784	-4,130	3,038	3,417	5,153	7,607	786	854	289	866	577	-253	194	-65	-120	7	195	-11	-73	153	0	0	0
Accrued expenses
-568	857	837	546	572	-607	-585	-750	-1,076	-1,101	580	-90	1,188	2,330	1,246	225	-1,700	-1,001	136	1,465	1,764	416	111	137	885	885	-27	-101	-127	-29	-14	94	109	-181	0	0	0
Accrued employee benefits
-32	-397	-815	-852	-675	-742	-172	154	229	1,761	266	35	-82	36	1,026	780	641	-261	311	391	1,110	535	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Lease liability
-224	-217	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred rent
-	-	-	-	-	-90	-88	-76	-40	-3	249	246	221	207	12	278	289	288	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gain on sale of equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Liabilities of discontinued operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	24	0	0	0
Net Cash Used In Operating Activities
-14,609	-13,873	-13,558	-14,098	-15,424	-17,279	-17,921	-18,843	-20,275	-20,204	-26,656	-28,115	-28,235	-27,901	0	0	0	-	-	-	-	-16,079	0	0	0	-	-	-	-	-8,916	-4,874	-4,343	-4,009	-2,875	0	0	0
Cash Flows From Investing Activities:
Net Cash Used In Operating Activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-
Purchases of property and equipment
-	-	-	-	-	-	-	-	-	212	579	535	536	569	243	485	527	501	462	88	62	48	54	44	37	36	28	23	13	10	0	0	0	-	-	-	-
Proceeds from the sale of equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	0	0	0
Net Cash From Investing Activities
0	0	-7	-7	-7	-7	-3	-201	-201	-212	-579	-535	-536	-569	0	0	0	-	-	-	-	-48	0	0	0	-	-	-	-	-10	2,783	-76	-76	-75	0	0	0
Cash Flows From Financing Activities:
Proceeds from issuance of common stock for stock option exercises
-	-	-	-	-	-	-	-	-	-	166	170	980	814	0	0	0	-	-	-	-	4	5	5	5	232	0	0	0	-	-	-	-	-	-	-	-
Proceeds from "at the market" stock issuance
-	-	-	-	-	-	-	-	-	6,358	7,234	7,423	1,778	1,509	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Cash Used In Investing Activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-
Proceeds from issuance of common stock for stock option exercises
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	0
Proceeds from issuance of common stock for warrant exercises
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-
Proceeds from issuance of common stock for warrant exercises
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Proceeds from issuance of common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Cash paid as direct offering costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Net Cash From Financing Activities
0	0	22,666	28,688	29,088	29,088	6,423	12,797	18,042	18,477	43,736	31,977	27,142	26,707	0	0	0	-	-	-	-	19,027	0	0	0	-	-	-	-	12,202	2,059	1,965	4,806	6,979	0	0	0
Net decrease in cash and cash equivalents
-14,609	-13,873	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Cash Provided By Financing Activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-
Net increase (decrease) in cash
-	-	-	-	-	-	-	-	-	-1,939	16,501	3,327	-1,629	-1,763	-27,257	5,292	3,051	3,293	28,520	-3,086	894	2,900	-1,859	966	2,635	4,671	568	945	1,718	3,276	-32	-2,454	721	4,029	0	0	0
Net decrease in cash and cash equivalents
-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Noncash Financing Activities:
Right of use asset from operating lease
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Right of use asset from operating lease
-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deemed dividends for accretion of Series B Preferred Stock discount
0	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
In-kind dividends paid in preferred stock
249	248	247	245	245	243	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash paid for interest
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cash paid for taxes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Series B Preferred Stock [Member]
Conversion of Series B Preferred Stock
0	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-